Literature DB >> 22337949

Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.

Gabriele Missale1, Massimo Pilli, Alessandro Zerbini, Amalia Penna, Lara Ravanetti, Valeria Barili, Alessandra Orlandini, Atim Molinari, Massimo Fasano, Teresa Santantonio, Carlo Ferrari.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) persistence is associated with impaired CD8 functions. Whether functional restoration of CD8 T cells chronically exposed to antigen can be obtained once the antigen is removed remains to be clarified.
OBJECTIVE: To determine whether clearance of HCV by antiviral treatment can fully restore the antiviral function of HCV-specific CD8 cells.
DESIGN: Peripheral blood HCV-, Flu- and cytomegalovirus (CMV)-specific CD8 cells were quantified by tetramer staining in 28 patients whose HCV infection resolved after peginterferon or peginterferon/ribavirin treatment for either acute or chronic hepatitis and in eight subjects with acute HCV infection which resolved spontaneously for comparison. HCV-specific CD8 cells were evaluated for their phenotypic and functional characteristics by comparing different patient groups and CD8 cells with different viral specificities in the same patients.
RESULTS: Sustained viral response (SVR) did not lead to full maturation of a functional memory CD8 cell response. In particular, SVR in chronic infection was associated with a greater level of T cell dysfunction than responders after acute infection, who showed HCV-specific CD8 responses comparable to those of spontaneous resolvers but weaker than those of Flu-specific CD8 cells. Higher programmed death (PD)-1 expression was detected on HCV than on Flu- and CMV-specific CD8 cells and the effect of PD-1/PD-L1 blockade was better in SVRs after chronic than after acute HCV infection.
CONCLUSION: A better restoration of HCV-specific CD8 function was detectable after SVR in patients with acute hepatitis than in those with chronic disease. Thus, the difficulty in achieving a complete restoration of the antiviral T cell function should be considered in the design of immunomodulatory therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22337949     DOI: 10.1136/gutjnl-2011-300515

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.

Authors:  Desarae Echevarria; Alexander Gutfraind; Basmattee Boodram; Jennifer Layden; Jonathan Ozik; Kimberly Page; Scott J Cotler; Marian Major; Harel Dahari
Journal:  Vaccine       Date:  2019-04-05       Impact factor: 3.641

Review 2.  Immune and non-immune responses to hepatitis C virus infection.

Authors:  Jiaren Sun; Ricardo Rajsbaum; MinKyung Yi
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Authors:  Yalena Amador-Cañizares; Gillian Martínez-Donato; Liz Alvarez-Lajonchere; Claudia Vasallo; Mariacarla Dausá; Daylen Aguilar-Noriega; Carmen Valenzuela; Ivette Raíces; Jean Dubuisson; Czeslaw Wychowski; Zurina Cinza-Estévez; Marlén Castellanos; Magdalys Núñez; Anny Armas; Yaimé González; Ismariley Revé; Ivis Guerra; Angel Pérez Aguiar; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 4.  Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C.

Authors:  Sabrina Mazouz; Maude Boisvert; Naglaa H Shoukry; Daniel Lamarre
Journal:  Can Liver J       Date:  2018-07-17

5.  Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses.

Authors:  Peng Peng Ip; Annemarie Boerma; Joke Regts; Tjarko Meijerhof; Jan Wilschut; Hans W Nijman; Toos Daemen
Journal:  Mol Ther       Date:  2013-12-27       Impact factor: 11.454

6.  Polyfunctional type-1, -2, and -17 CD8⁺ T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection.

Authors:  Debora Franceschini; Paola Del Porto; Silvia Piconese; Emanuele Trella; Daniele Accapezzato; Marino Paroli; Stefania Morrone; Enza Piccolella; Enea Spada; Alfonso Mele; John Sidney; Alessandro Sette; Vincenzo Barnaba
Journal:  PLoS Pathog       Date:  2012-06-21       Impact factor: 6.823

7.  Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Authors:  Desarae Echevarria; Alexander Gutfraind; Basmattee Boodram; Marian Major; Sara Del Valle; Scott J Cotler; Harel Dahari
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

8.  T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.

Authors:  Benoit Callendret; Heather B Eccleston; Shelby Hall; William Satterfield; Stefania Capone; Antonella Folgori; Riccardo Cortese; Alfredo Nicosia; Christopher M Walker
Journal:  Hepatology       Date:  2014-09-25       Impact factor: 17.425

9.  New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology.

Authors:  Svetlana Gorodin; Serhat Unal; Youchun Wang; Mikhail I Mikhaylov; Ludmila Bigbulatova; Tamar Jehuda-Cohen
Journal:  ScientificWorldJournal       Date:  2013-02-14

10.  Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity.

Authors:  Alla Kachko; Sharon E Frey; Lev Sirota; Ranjit Ray; Frances Wells; Iryna Zubkova; Pei Zhang; Marian E Major
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.